drugset
drugset / Trial / NCT05022901

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

NCT05022901 ↗

Phase 3 Active not recruiting 30 enrolled Delcath Systems Inc.
NaSingle-groupOpen-labelTreatment

Summary

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.

Timeline

Start
2022-06-10
Primary completion
2024-03-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 3 mg/kg Other

Indications

uveal melanoma